guest ::
| Home > Publications database > Neo-antigen tumor vaccination depends on CD4-licensing conveyed by adeno-associated virus like particles. > print |
| Home > Publications database > Neo-antigen tumor vaccination depends on CD4-licensing conveyed by adeno-associated virus like particles. > print |
| 001 | 303025 | ||
| 005 | 20250727021634.0 | ||
| 024 | 7 | _ | |a 10.1016/j.ymthe.2025.07.014 |2 doi |
| 024 | 7 | _ | |a pmid:40671675 |2 pmid |
| 024 | 7 | _ | |a 1525-0016 |2 ISSN |
| 024 | 7 | _ | |a 1525-0024 |2 ISSN |
| 024 | 7 | _ | |a altmetric:179392190 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2025-01472 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Neukirch, Lasse |0 P:(DE-He78)baf300324dc6b20752a9a684a2841381 |b 0 |e First author |
| 245 | _ | _ | |a Neo-antigen tumor vaccination depends on CD4-licensing conveyed by adeno-associated virus like particles. |
| 260 | _ | _ | |a Amsterdam |c 2025 |b Elsevier |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1753097944_5171 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #EA:D120#LA:D210# / epub |
| 520 | _ | _ | |a Personalized treatment has become a realistic option for tumor patients, accelerated by significantly reduced sequencing costs of tumor genomes and advances in vaccine formulations. The druggability of cancer neo-antigens caused by individual mutations is centered in this effort. We here use an AAV-based VLP platform to compose a neo-antigen specific protein vaccine that is effective in a murine prevention and treatment setting. Furthermore, we show that CD4+ T cell responses that are provided by the AAV capsid are crucial for an effective murine melanoma treatment. To uncover the optimal composition of a peptide vaccine we de-linked MHC-II helper peptides from the capsid and formulated an efficient neo-antigen specific vaccine, which showed the independence of CD4+ T cell response from tumor sequences. The findings are supported by clinical data of neo-antigen vaccinated tumor patients. Our results punctuate on the significance of MHC-II epitopes for CD8+ T cell responses and suggest a future use of AAVLPs as neo-epitope vaccines in personalized cancer treatments. |
| 536 | _ | _ | |a 314 - Immunologie und Krebs (POF4-314) |0 G:(DE-HGF)POF4-314 |c POF4-314 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 700 | 1 | _ | |a Uhrig-Schmidt, Silke |0 P:(DE-He78)c582340f180b3ff6ea9f732f17047d3e |b 1 |e First author |u dkfz |
| 700 | 1 | _ | |a von Werthern, Katharina |0 P:(DE-He78)340faceb181495b537c5b0031a305167 |b 2 |u dkfz |
| 700 | 1 | _ | |a Tuch, Alexandra |0 P:(DE-He78)5ab3e75a5a7c0a8d804f9833a1152067 |b 3 |u dkfz |
| 700 | 1 | _ | |a Kraske, Joscha A |b 4 |
| 700 | 1 | _ | |a Lyu, Yanhong |0 P:(DE-He78)558f7ddc9b9893d0f57eb74e243cc4fd |b 5 |u dkfz |
| 700 | 1 | _ | |a Lenoir, Bénédicte |0 P:(DE-He78)4671d97058e8d2ddb314e6be4de0c403 |b 6 |u dkfz |
| 700 | 1 | _ | |a Eichmüller, Stefan |0 P:(DE-He78)23fb8cfffbf2aa8eee5d51af417ad944 |b 7 |u dkfz |
| 700 | 1 | _ | |a Meyer, Marten |0 P:(DE-He78)27b8b96bde8e36bbbc5e91485b08411a |b 8 |u dkfz |
| 700 | 1 | _ | |a Zörnig, Inka |b 9 |
| 700 | 1 | _ | |a Jäger, Dirk |0 P:(DE-He78)ed0321409c9cde20b380ae663dbcefd1 |b 10 |u dkfz |
| 700 | 1 | _ | |a Schmidt, Patrick |0 P:(DE-He78)0a9ff2c74a3fef06f552be5bb95bfd2d |b 11 |e Last author |u dkfz |
| 773 | _ | _ | |a 10.1016/j.ymthe.2025.07.014 |g p. S1525001625005490 |0 PERI:(DE-600)2001818-6 |p nn |t Molecular therapy |v nn |y 2025 |x 1525-0016 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:303025 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)baf300324dc6b20752a9a684a2841381 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)c582340f180b3ff6ea9f732f17047d3e |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-He78)340faceb181495b537c5b0031a305167 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-He78)5ab3e75a5a7c0a8d804f9833a1152067 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-He78)558f7ddc9b9893d0f57eb74e243cc4fd |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 6 |6 P:(DE-He78)4671d97058e8d2ddb314e6be4de0c403 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 7 |6 P:(DE-He78)23fb8cfffbf2aa8eee5d51af417ad944 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 8 |6 P:(DE-He78)27b8b96bde8e36bbbc5e91485b08411a |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 10 |6 P:(DE-He78)ed0321409c9cde20b380ae663dbcefd1 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 11 |6 P:(DE-He78)0a9ff2c74a3fef06f552be5bb95bfd2d |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-314 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Immunologie und Krebs |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b MOL THER : 2022 |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2025-01-06 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2025-01-06 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2025-01-06 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2025-01-06 |
| 915 | _ | _ | |a IF >= 10 |0 StatID:(DE-HGF)9910 |2 StatID |b MOL THER : 2022 |d 2025-01-06 |
| 920 | 2 | _ | |0 I:(DE-He78)D210-20160331 |k D210 |l GMP-Einheit Zelluläre Therapie |x 0 |
| 920 | 0 | _ | |0 I:(DE-He78)D120-20160331 |k D120 |l Angewandte Tumor-Immunität |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)D120-20160331 |k D120 |l Angewandte Tumor-Immunität |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)D210-20160331 |k D210 |l GMP-Einheit Zelluläre Therapie |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)D120-20160331 |
| 980 | _ | _ | |a I:(DE-He78)D210-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|